Aegerion Pharma Cancels Another IPO

Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug company focused on cardiovascular and metabolic diseases, has withdrawn registration for an $86.25 million IPO, due to “market conditions.” This is the second time in as many years that Aegerion has canceled a proposed IPO.


It had planned to trade on the Nasdaq, with Piper Jaffray and Thomas Weisel serving as co-lead underwriters. Aegerion has raised around $44 million in total VC funding, from firms like Index Ventures, Advent International, Alta Partners, Scheer & Co. and MVM Life Science Partners.